Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
Conditions
Interventions
Mycophenolate Mofetil/Mycophenolic Acid
Obinutuzumab
+3 more
Locations
46
United States
Univ of California, San Diego
La Jolla, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Emory Uni ; Division of Rheumatology
Atlanta, Georgia, United States
Suny Downstate Medical Center; Rheumatology
Brooklyn, New York, United States
North Shore - Long Island Jewish Hospital Health System; Rheumatology & Allergy- Clinical Immunology
Great Neck, New York, United States
Columbia University Medical Center
New York, New York, United States
Start Date
November 13, 2015
Primary Completion Date
January 15, 2019
Completion Date
August 2, 2023
Last Updated
August 27, 2024
NCT05126277
NCT07015983
NCT06947460
NCT07107659
NCT07225387
NCT05934149
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions